The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Although ‘lean type 2 diabetes’ is not uncommon, clinicians must first exclude other causes including autoimmune, monogenic, ...

In today's dynamic and volatile market terrain, investors are increasingly drawn to opportunities that promise robust growth ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Eli Lilly’s stock closed at $786.92, marking a 1.19% gain, outpacing the broader market. Despite a 3.66% drop in the past ...

Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...

Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

While weight-loss treatments continue to dominate the conversation around LLY stock, UBS notes that the company has a strong ...